Coherus Biosciences | CHRS - Ebitda


Coherus Biosciences reported $-43.33M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
AbbVie USD 6.91B 3.22B Jun/2026
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
ALKERMES USD 120.06M 19.15M Sep/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Amarin USD 12.54M 28.57M Jun/2025
Amgen USD 5.8B 1.25B Sep/2026
Baxter International USD 474M 165M Jun/2026
Biogen USD 450.8M 198.9M Jun/2026
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Eli Lilly USD 9.46B 3.54B Sep/2026
Fujifilm JPY 143.41B 41.8B Sep/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
Merck USD 1.42B 2.97B Jun/2026
Myriad Genetics USD 14.3M 4M Dec/2025
Pacira USD 50.45M 1.78M Sep/2026
Perrigo USD 156.6M 83M Sep/2026
Pfizer USD 6.36B 350M Sep/2026
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
Teva Pharmaceutical Industries USD 1.5B 1.02B Sep/2026
Vertex Pharmaceuticals USD 888.6M 436.6M Sep/2026
Xencor USD 25.1M 59.73M Sep/2026
Zoetis USD 1.07B 21M Sep/2026